Letter ·
NAMD Highlights Concerns with Proposed Pharmacy Value-Based Purchasing Rule
On July 20, 2020, NAMD submitted comments to the Centers for Medicare and Medicaid Services on a proposed rule seeking to promote value-based purchasing in pharmaceuticals.
The proposed rule would allow pharmaceutical manufacturers to report multiple “best prices” under the Medicaid Drug Rebate Program unique to specific value-based purchasing arrangements. In the letter, NAMD expresses concern that this would undermine state pharmacy budgets and create strong incentives for pharmaceutical manufacturers to game the “best price.”
Related resources
NAMD Comments on Senate Finance Committee’s Generic Drug Legislation
The legislation would exclude most generic drugs from the Medicaid Drug Rebate Program's inflationary rebates.
NAMD Submits Comments on Medicaid Drug Rebate Program Proposed Rule
On July 25, NAMD submitted comments on CMS's proposed rule on the Medicaid Drug Rebate Program (MDRP).
Stay Informed
Drop us your email and we’ll keep you up-to-date on Medicaid issues.